Acetylcholinesterase

Class

synthetic huperzine A analog; acetylcholinesterase inhibitor (also reported to raise cortical GABA)

Pathway

inhibits acetylcholinesterase, increasing cortical acetylcholine, which in turn is reported to raise cortical GABA levels, a seizure-inhibitory neurotransmitter

Acetylcholinesterase (AChE) is the enzyme responsible for breaking down acetylcholine, a neurotransmitter that carries signals across synapses in both the brain and the peripheral nervous system. By inhibiting AChE, acetylcholine persists longer in the synaptic space, prolonging its stimulatory effect on downstream neurons. This general strategy has long been used to boost cholinergic signaling in disorders where it is deficient, most notably Alzheimer's disease, and to strengthen neuromuscular transmission in conditions such as myasthenia gravis. A less familiar application, reflected in this mechanism, is the observation that elevated cortical acetylcholine can secondarily increase levels of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. Because insufficient GABAergic inhibition is a recognized contributor to seizure activity, augmenting acetylcholine as an indirect route to raising GABA represents a distinct rationale for AChE inhibition, separate from its traditional cognitive applications. This dual profile situates AChE-inhibiting compounds at the intersection of cognitive and seizure-related neuropharmacology, broadening the disease contexts in which modulating this single enzyme may be relevant.